% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Weichenhan:292145,
author = {D. Weichenhan$^*$ and A. Riedel$^*$ and E. Sollier$^*$ and
U. Toprak$^*$ and J. Hey$^*$ and K. Breuer$^*$ and J. A.
Wierzbinska$^*$ and A. Touzart$^*$ and P. Lutsik$^*$ and M.
Bähr$^*$ and A. Östlund and T. Nilsson and S. Jacobsson
and A. Waraky and Y. L. Behrens and G. Göhring and B.
Schlegelberger and C. Steinek and H. Harz and H. Leonhardt
and A. Dolnik and D. Reinhardt and L. Bullinger and L.
Palmqvist and D. Lipka$^*$ and C. Plass$^*$},
title = {{A}ltered enhancer-promoter interaction leads to {MNX}1
expression in pediatric acute myeloid leukemia with
t(7;12)(q36;p13).},
journal = {Blood advances},
volume = {8},
number = {19},
issn = {2473-9529},
address = {Washington, DC},
publisher = {American Society of Hematology},
reportid = {DKFZ-2024-01633},
pages = {5100-5111},
year = {2024},
note = {#EA:B370#EA:B087#LA:B370#LA:B340# / 2024 Oct
8;8(19):5100-5111},
abstract = {Acute myeloid leukemia (AML) with the t(7;12)(q36;p13)
translocation occurs only in very young children and has a
poor clinical outcome. The expected oncofusion between
breakpoint partners (MNX1 and ETV6) has only been reported
in a subset of cases. However, a universal feature is the
strong transcript and protein expression of MNX1, a homeobox
transcription factor that is normally not expressed in
hematopoietic cells. Here, we map the translocation
breakpoints on chromosomes 7 and 12 in affected patients to
a region proximal to MNX1 and either introns 1 or 2 of ETV6.
The frequency of MNX1 overexpression in pediatric AML
(n=1556, own and published data) is $2.4\%$ and occurs
predominantly in t(7;12)(q36;p13) AML. Chromatin interaction
assays in a t(7;12)(q36;p13) iPSC cell line model unravel an
enhancer-hijacking event that explains MNX1 overexpression
in hematopoietic cells. Our data suggest that
enhancer-hijacking may be a more widespread consequence of
translocations where no oncofusion product was identified,
including e.g. t(1;3) or t(4;12) AML.},
cin = {B370 / B087 / B340 / HD01},
ddc = {610},
cid = {I:(DE-He78)B370-20160331 / I:(DE-He78)B087-20160331 /
I:(DE-He78)B340-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39121370},
doi = {10.1182/bloodadvances.2023012161},
url = {https://inrepo02.dkfz.de/record/292145},
}